ONCIMMUNE LEADING EARLY CANCER DETECTION
 
ONCIMMUNE LEADING EARLY CANCER DETECTION

EarlyCDT-Lung results for general risk assessment are reported as High Level, Moderate Level or No Significant Level of Autoantibodies Detected

  • A High Level test result is defined as one or more autoantibodies in the EarlyCDT-Lung panel being above the high cut-off value
  • A Moderate Level test result is defined as one or more autoantibodies in the EarlyCDT-Lung panel being above the low cut-off value but all are below the high cut-off value
  • A No Significant Level of Autoantibodies Detected test result is defined as all autoantibodies in the EarlyCDT-Lung panel being below the low cut-off value

What if the patient’s test result is High Level or Moderate Level?

  • A High Level result indicates that the patient is at 16x greater risk of lung cancer than that predicted by gender, age, smoking history and other risk factors. For a Moderate Level result, the increase in risk is 3x
  • This increased risk may warrant a recommendation for additional testing, which may include CT imaging. The recommendation will be consistent with the patient’s history and overall risk profile, which could include prior radiological findings
  • If lung cancer is not found, a physician may recommend continued additional testing in the future. Other age- and gender-specific screenings for other cancers (for example, breast and colon), as recommended by the American Cancer Society (www.cancer.org), may also be considered

What if the patient’s test result is No Significant Level of Autoantibodies Detected?

  • A No Significant Level of Autoantibodies Detected test result indicates a lower likelihood of lung cancer than a Moderate or High Level result. This result does not rule out lung cancer now or in the future. This is because in order to be eligible for the test, the patient is already at an elevated risk of lung cancer as predicted by age, gender, smoking history and other risk factors. This risk has not changed appreciably

The physician will determine continued monitoring and follow-up consistent with the patient’s history and overall risk profile

PLEASE READ THE FOLLOWING STATEMENT CAREFULLY

Electronic versions of the materials you are seeking to access are being made available on this website by Oncimmune Holdings plc (the “Company”).

These materials are not directed to nor are they intended for access by persons located or resident in the United States, Australia, Canada, South Africa, Japan or any other jurisdiction where to do so would constitute a violation of the relevant laws or regulations of such jurisdiction.

None of the securities of Company discussed or referred to in the materials you are seeking to access have been registered under the US Securities Act or 1933, as amended (the “Securities Act”) and may not be offered, sold, pledged or otherwise transferred except (1) in an offshore transaction meeting the requirements of Rule 903 or Rule 904 of Regulation S under the Securities Act, (2) pursuant to an effective registration statement under the Securities Act, or (3) pursuant to an available exemption from the registration requirements of the Securities Act, in each case in accordance with all applicable securities laws.

By clicking the “SUBMIT” button below you confirm that you (1) have read and understood the information set out above, (2) agree to be bound by its terms, (3) are not located in the United States and do not have a registered address in, and are not resident or located in, Australia, Canada, South Africa or Japan and (4) are permitted under applicable law and regulation to proceed to the following parts of this website.

Please click on the button below to confirm that you have read, understood and agree with the disclaimer above.

Yes, I accept No, I don't accept